Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: experience of one centre

Transpl Immunol. 2005 Jun;14(2):91-7. doi: 10.1016/j.trim.2005.03.013. Epub 2005 Apr 25.

Abstract

In this retrospective study, we analyzed the effect of the presence of anti-donor preformed alloantibodies in 268 liver allograft transplants. Crossmatches were performed by complement-dependent cytotoxicity (CDC) assay and HLA antibody screening by flow cytometry (FlowPRA). Positive anti-donor crossmatch was detected in 5.2% of transplants. Acute rejection frequency in +CDC crossmatch patients was not different from that observed in -CDC crossmatch patients. None of the patients transplanted with +CDC crossmatch developed chronic rejection, but they showed a significantly lower allograft survival rate, and the majority of them had allograft failures before the end of the first post-transplant year, mainly within the 3 first months. Indeed, positive FlowPRA determination was concordant with data from the CDC assay. In conclusion, these findings show a direct correlation between the presence of anti-donor preformed antibodies and a poor allograft survival in liver transplant.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antilymphocyte Serum / blood*
  • Biomarkers / blood
  • Female
  • Graft Rejection / blood*
  • Graft Rejection / mortality
  • Graft Survival
  • Humans
  • Liver Diseases / blood
  • Liver Diseases / therapy*
  • Liver Transplantation* / mortality
  • Male
  • Prognosis
  • Tissue Donors*
  • Transplantation, Homologous

Substances

  • Antilymphocyte Serum
  • Biomarkers